This looked at patients with transplant-eligible newly diagnosed multiple myeloma, and randomly assigned the patients ... I ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

With a median follow-up duration of 55 months, the tandem ASCT group had a median PFS of 42 months compared with 62 months in the single ASCT group. In a real-world study involving patients with ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

At six months, the median PFS rates were 89.5% and 87.6% in the ... for the treatment of KRd56 and KRd27 in patients with relapsed or refractory multiple myeloma. However, it’s important to note that ...

CAMBRIDGE, Mass., November 12, 2024--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent ...